Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 7,478 shares, an increase of 72.8% from the December 15th total of 4,327 shares. Based on an average trading volume of 75,968 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are short sold. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 75,968 shares, the days-to-cover ratio is presently 0.1 days.

Barinthus Biotherapeutics Stock Performance

BRNS opened at $0.73 on Friday. The company has a market cap of $29.81 million, a price-to-earnings ratio of -0.39 and a beta of -0.66. Barinthus Biotherapeutics has a one year low of $0.64 and a one year high of $2.92. The business’s fifty day moving average is $0.74 and its two-hundred day moving average is $1.09.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Friday, November 7th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.09. On average, analysts predict that Barinthus Biotherapeutics will post -1.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Baird Financial Group Inc. raised its stake in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 192,461 shares of the company’s stock after buying an additional 100,000 shares during the quarter. Baird Financial Group Inc. owned about 0.48% of Barinthus Biotherapeutics worth $179,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Wall Street Analysts Forecast Growth

BRNS has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a report on Monday, December 22nd. HC Wainwright upped their price objective on Barinthus Biotherapeutics from $3.00 to $4.00 and gave the stock a “buy” rating in a report on Monday, November 17th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $4.00.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.